Compare Amylx Pharmaceuticals Inc (AMLX) vs CubeSmart (CUBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs CubeSmart — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while CubeSmart trades at $40.16 (market cap $9.10B). The key difference: CubeSmart is far larger — about 4.6× Amylx Pharmaceuticals Inc's market cap, and CubeSmart pays a 5.27% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CUBE | |
|---|---|---|
Market Cap | $1.98B | $9.10B |
Sector | Health | Real Estate |
52-Week High | $18.70 | $42.34 |
52-Week Low | $7.64 | $35.36 |
Enterprise Value | $1.70B | $12.60B |
Dividend Yield | — | 5.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
CubeSmart (CUBE) trades at $40.19, up 1.01% with a bearish technical signal despite recent earnings beats. The REIT maintains strong profitability with 28.93% net margins and offers a 5.3% dividend yield. Analyst consensus shows mixed sentiment with 41% buy ratings but a $43.86 price target suggesting 9% upside. Recent news highlights Q2 2026 earnings anticipation on July 30, 2026, while institutional investors have been trimming positions.
The stock presents value with reasonable valuation multiples (P/E 28.1, P/S 8.13) and consistent cash flow generation, though high debt levels and interest rate sensitivity pose risks. Near-term performance will depend on Q2 earnings results and macroeconomic conditions affecting the self-storage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
